Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
11/03/2022 - 09:06 AM
Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia
SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced acceptance of a poster presentation at 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana. Details of the presentation, which will be presented live, are as follows:
Title: "Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" Date/Time: Sunday, December 11, 2022, 6:00 PM-8:00 PMPresenter: Justin M. Watts, MD, Associate Professor of Medicine Section Chief, Leukemia, Pap Corps Endowed Professor in Leukemia, Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine
About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes of cancer patients. For more information, please visit www.aptevotherapeutics.com .
CONTACT: Miriam Weber Miller Aptevo Therapeutics Email: IR@apvo.com or Millerm@apvo.com Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View source version on accesswire.com: https://www.accesswire.com/723685/Aptevo-Therapeutics-Announces-Poster-Presentation-at-the-64th-American-Society-of-Hematology-Annual-Meeting-and-Exposition
APVO Rankings
N/A Ranked by Stock Gains
APVO Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Seattle
About APVO
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.